News
02-26-2013, 07:50 AM
Quinten, a strategic and operational consulting company specializing in the evaluation of biomedical data in the pharmaceutical, biotechnology and cosmetic industries, today announces the identification of two discriminating biological marker candidates which are indicative of a favorable response to treatment in women suffering from triple-negative breast cancer (TNBC).
More... (http://www.news-medical.net/news/20130226/Two-discriminating-biological-markers-found-to-predict-a-favorable-response-to-treatment-in-triple-negative-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20130226/Two-discriminating-biological-markers-found-to-predict-a-favorable-response-to-treatment-in-triple-negative-breast-cancer.aspx)